Adverse Responses to Drugs in Man: Critical Comparison of Reported Toxicological Findings in Minipigs and Humans

The Minipig in Biomedical Research

Volumn , Issue , 2011, Pages 573-594

  Ganderup, Niels Christian ^a  

^a Ellegaard A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84899878644     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b11356-43     Document Type: Chapter

References (144)

1. Adapalene Benzoyl Peroxide, Anonymous, 2007. FDA CDER Pharmacology Review for NDA 22-320. Signed by reviewer 5DEC2007. [PharmR 022320s-000 (05DEC2007)].
2. Adapalene Benzoyl Peroxide, Anonymous, 2008. FDA CDER Label for NDA 22-320. Revision date DEC2008. [022320/S-000 08DEC2008].
3. Alendronate, Anonymous, 1995a. FDA CDER Administrative documents for NDA 20-560 Part 01. [Administrative documents 020560 Part 01 (1995-jul-13)].
4. Alendronate, Anonymous, 1995b. FDA CDER Administrative documents for NDA 20-560 Part 02. [Administrative documents 020560 Part 02 (1995-jul-13)].
5. Alendronate, Anonymous, 1995c. FDA CDER Medical Officer Review for NDA 20-560 Part 01. [Medical Officer Review 020560 Part 01 (1995-aug-24)].
6. Alendronate, Anonymous, 1999. FDA CDER Medical Officer Review for NDA 20-560 Part 02. [Medical Officer Review 020560 Part 02 (1995-aug-24)].
7. Alendronate, Anonymous, 1995e. FDA CDER Pharmacology Review for NDA 20-560. [Pharmacology Review 020560 (1995-sep-01)].
8. Alendronate, Anonymous, 1999. FDA CDER Pharmacology Review for NDA 20-835s000 Part 01. [Pharmacology Review 020835s-000 Part 01 (1998-jan-09)].
9. Avobenzone Ecamsule Octocrylene Titanium Dioxide, Anonymous, 2006. Medical-Clinical Review 021471s-000 Part 01. Memorandum dated October 4, 2006. [021471s-000 Part 01].
10. Avobenzone Ecamsule Octocrylene, Anonymous, 2006. Pharmacology Review for 021502s-000. Date of review submission to Division File System (DFS): 2-2-2006. [021502s-000].
11. Avobenzone Ecamsule Octocrylene, Anonymous, 2009. FDA-CDER Medical-Clinical Review for NDA 21-501. [021501s-000 Part 02 2009-okt-02].
12. Babilas, P., Karrer, S., Sidoroff, A. et al., 2005. Photodynamic therapy in dermatology-An update. Photodermatology, Photoimmunology and Photomedicine 21:142-9.
13. Bode, G., Clausing, P., Gervais, F. et al., 2010. The utility of the minipig as an animal model in regulatory toxicology. Journal of Pharmacological and Toxicological Methods 62(3): 196-220.
14. Bourré, L., Giuntin, F., Eggleston, I.M. et al., 2008. 5-Aminolaevulinic acid peptide prodrugs enhance photosensitization for photodynamic therapy. Molecular Cancer Therapeutics 7(6):1720-9.
15. Bramos, D., Tsirikos, N., Kottis, G. et al., 2008. The acute effect of an echo-contrast agent on right ventricular dimensions and contractility in pigs. Journal of Cardiovascular Pharmacology 51(1):86-91.
16. Bril, A., Slivjak, M., DiMartino, M.J. et al., 1992. Cardioprotective effects of carvedilol, a novel beta adrenoceptor antagonist with vasodilating properties, in anaesthetised minipigs: Comparison with propranolol. Cardiovascular Research 26(5):518-25.
17. Busch, U., Schmid, J., Heinzel, G. et al., 1998. Pharmacokinetics of meloxicam in animals and the relevance to humans. Drug Metabolism and Disposition 26(6):576-84.
18. Calcipotriene Betamethasone, Anonymous, 2007. FDA CDER Pharmacology Review for NDA 21-852. Dated 15AUG2007. [021852/S000_PharmR (15AUG2007)].
19. Calcipotriene Betamethasone, Anonymous, 2010. FDA CDER Label for NDA 21-852. Dated 30MAR2010. [Label 021852s006 (30MAR2010)].
20. Calcipotriene, Anonymous, 1994. FDA CDER Administrative correspondence for NDA 20-554. Dated 14JUL1994. [820554_Calcipotriene_corres_14_Jul_94].
21. Calcipotriene, Anonymous, 1995. FDA CDER Pharmacology Review for NDA 20-273 reviewed in IND 20-554. Dated 01MAY1995. [020554 Calcipotriene Pharmacology Review (01 May 95)].
22. Calcipotriene, Anonymous, 2007. Combined label for NDA’s 20-611, 20-554, and 20-273. Dated 26SEP2007. [Label 020611s007, 020554s007, 020273s009 (26SEP2007)].
23. Calcitonin, Anonymous, 1994a. FDA CDER Administrative documents 017769 Part 01 for NDA 17-769. [Administrative documents 017769 Part 01 (1994-nov-18)].
24. Calcitonin, Anonymous, 1994b. FDA CDER Administrative documents 017769 Part 02 NDA 17-769. [Administrative documents 017769 Part 02 (1994-nov-18)].
25. Calcitriol, Anonymous, 2008. FDA CDER Pharmacology review for NDA 22-087. Dated 30JUN2008. [PharmR022087/S-000 30JUN2008].
26. Calcitriol, Anonymous, 2009. FDA CDER Label for NDA 22-087. Dated 04FEB2009. Label 022087/S-000 (2009-feb-04)].
27. Carvedilol, Anonymous, 1994. Original pharmacology review and evaluation of NDA 20-297. [020297_Carvedilol_pharmr_P1_22_Apr_94].
28. Cheer, S.M. and Plosker, G.L., 2001. Tacrolimus ointment. A review of its therapeutic potential as a topical therapy in atopic dermatitis. American Journal of Clinical Dermatology 2(6):389-406.
29. Clindamycin Benzoyl Peroxide, Anonymous, 2000. FDA CDER Pharmacology review for NDA 50-741. Date stamped 22AUG2000. [50-741/S000 PharmR].
30. Clindamycin Benzoyl Peroxide, Anonymous, 2009. FDA CDER Label for clindamycin; Benzoyl peroxide. [050756s-034_DUAC_lbl].
31. Clindamycin Tretinoin, Anonymous, 2004. FDA CDER Pharmacology Review for NDA 50-802. 050802/S-000 (2004-feb-06).
32. Clindamycin Tretinoin, Anonymous, 2006a. FDA CDER Label for IND 50-802. Dated 01NOV2006. [Clindamycin; Tretinoin]. [Label 050802/S-000 2006-nov-01].
33. Clindamycin Tretinoin, Anonymous, 2006b. FDA CDER Medical Clinical Review for NDA 50-802. [050802s-000 (2006-may-05)].
34. Clobetasol propionate, Anonymous, 2003a. FDA CDER Label for NDA 21-644. Date of approval 06MAY2003b. [21-644_Label Clobex (06MAY2003)].
35. Clobetasol propionate, Anonymous, 2003b. FDA CDER Pharmacology review for NDA 21-644. Date reviewed by Centre 06MAY2003. [21-644_Clobex_pharmr (06MAY2003)].
36. Clobetasol propionate, Anonymous, 2004. FDA CDER Label for NDA 21-835. Dated 05FEB2004. [021835s000_PRNTLBL (05FEB2004)].
37. Clobetasol propionate, Anonymous, 2005. FDA CDER Pharmacology Review for NDA 21-835. Dated 08SEP2005. [021835s000_PharmR (08SEP2005)].
38. Davies, N.M. and Skjodt N.M., 1999. Clinical pharmacokinetics of meloxicam. A cyclo-oxygenase-2 preferential nonsteroidal anti-inflammatory drug. Clinical Pharmacokinetics. 36(2): 115-26.
39. Diclofenac Sodium, Anonymous, 2000. FDA CDER Pharmacology review part 02 for NDA 21-005. Date stamped JUL162000. [021005s-000 Part 01 [2000-jul-16].
40. Diclofenac Sodium, Anonymous, 2005. FDA CDER Label for NDA 21-005. [Label 021005s-000].
41. Dijkmans, P.A., Visser, C.A., and Kamp, O., 2005. Adverse reactions to ultrasound contrast agents: Is the risk worth the benefit? European Journal of Echocardiography 6:363-6.
42. Donnelly, R.F., Morrow, D.I., McCarron, P.A. et al., 2007. Influence of solution viscosity and injection protocol on distribution patterns of jet injectors: Application to photodynamic tumour targeting. Journal of Photochemistry and Photobiology B 89(2-3):98-109.
43. Dronedarone, Anonymous, 2009. FDA CDER Pharmacology review for NDA 22-425. Dated 30APR2009. [PharmR 022425/S-000 Part 02 (30APR2009)].
44. Ecallantide, Anonymous, 2009a. FDA CDER Label for NDA 125-277. Dated 27NOV2009. [Label 125277/S-000 (27NOV2009)].
45. Ecallantide, Anonymous, 2009b. FDA CDER Pharmacology review part 03 for NDA 125-277. Dated 29OCT2009. [PharmR 125277/S-000 Part 03 (29OCT2009)].
46. Eflornithine, Anonymous, 2000. FDA CDER Pharmacology Review Part 2 for NDA 21-145. Review completion date13JUN2000. 21145_Vaniqa_pharmr_P2.
47. Eflornithine, Anonymous, 2010. EMA EPAR Vaniqa-Product Information [last updated 23MAR2010].
48. Enfuvirtide, Anonymous, 2002a. FDA CDER Pharmacology Review Part 1 for NDA 21-481. Review completion date November 25 2002. [21481_Fuzeon_Pharmr_P1].
49. Enfuvirtide, Anonymous, 2002b. FDA CDER Pharmacology Review Part 4 for NDA 21-481. Review completion date November 25 2002. [21481_Fuzeon_Pharmr_P4].
50. Enfuvirtide, Anonymous, 2010. EMA EPAR-Product Information [last updated 07MAY2010].
51. Engelhardt, G., Homma, D., Schlegel, K. et al., 1995. Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance. Inflammation Research 44(10):423-33.
52. Everolimus, Anonymous, 2009a. FDA CDER Label for NDA 22-334. Dated 12MAR2009. [Label 022334/S-000 (12MAR2009)].
53. Everolimus, Anonymous, 2009b. FDA CDER Pharmacology review for NDA 22-334. Dated 12MAR2009. [PharmR 022334/S-000 (12MAR2009)].
54. Fluocinolone Acetonide; Hydroquinone; Tretinoin, Anonymous, 2000. FDA CDER Medical review for NDA 21-112. Date stamped 13JAN2000. [21-112_TRI-Luma_medr_P1].
55. Fluocinolone Acetonide; Hydroquinone; Tretinoin, Anonymous, 2001. FDA CDER Pharmacology review Part 2 for NDA 21-112. Signed by the three reviewers on 17 and 18DEC2001. [21-112_TRI-Luma_pharmr_P2].
56. Fluocinolone Acetonide; Hydroquinone; Tretinoin, Anonymous, 2002. FDA CDER Label for NDA 21-112. Signed by reviewer 18JAN2002. [21112lbl].
57. Fluocinonide, Anonymous, 2004. Pharmacology review for NDA 21-758. Dated 13DEC2004. [021758/S-000 (13DEC2004)].
58. Fluocinonide, Anonymous, 2010. Label for NDA 21-758. Dated 09MAR2010. [Label 021758/S-012 (09MAR2010)]
59. Fluorouracil, Anonymous, 2000. FDA CDER Pharmacology review part 02 for NDA 20-985. [PharmR 020985/S-000 Part 02 (13JUL2000)].
60. Fluorouracil, Anonymous, 2003. FDA CDER Label for NDA 20-985. [Label 020985/S-000 (13DEC2003)].
61. Fonacier, L., Spergel, J. Charlesworth, E.N. et al., 2005. Report of the topical calcineurin inhibitor task force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy. Journal of Allergy and Clinical Immunology 115(6):1249-53.
62. Fosse, T.K., Haga, H.A., Hormazabal, V. et al., 2008. Pharmacokinetics and pharmacodynamics of meloxicam in piglets. Journal of Veterinary Pharmacology and Therapeutics 31(3):246-52.
63. Ganderup, N.C., Earl, L., Bouches, C. et al., 2011. Survey of minipig clinical biochemistry, coagulation, and urinalysis parameters in the European pharmaceutical industry. Eurotox 2011, Paris.
64. Gates, B.J., Nguyen, T.T., Setter, S.M. et al., 2005. Meloxicam: A reappraisal of pharmacokinetics, efficacy and safety. Expert Opinion on Pharmacotherapy 12:2117-40.
65. Girod, V., Dapzol, J., Bouvier, M. et al., 2002. The COX inhibitors indomethacin and meloxicam exhibit anti-emetic activity against cisplatin-induced emesis in piglets. Neuropharmacology 42(3):428-36.
66. Herman, E.H., Ferrans, V.J., Young, R.S. et al., 1988. Examination of minoxidil-induced acute cardiotoxicity in miniature swine. Toxicology 48(1):41-51.
67. Herman, E.H., Ferrans, V.J., Young, R.S. et al., 1989. A comparative study of minoxidil-induced myocardial lesions in beagle dogs and miniature swine. Toxicologic Pathology 17(1 Pt 2):182-92.
68. Insulin Detemir, Anonymous, 2003. FDA CDER Pharmacology and toxicology review for NDA 21-536. Dated August 4, 2003. [021-536_Levemir_pharmr].
69. Insulin Detemir, Anonymous, 2006. EMA EPAR-Scientific Discussion [dated 15AUG2006].
70. Insulin Detemir, Anonymous, 2007. FDA CDER Label for NDA 21-536. Dated 29MAY2007. [Label 21-536 (29MAY2007)].
71. Jacobs, A., 2006. Use of non-traditional animals for evaluation of pharmaceutical products. Expert Opinion on Drug Metabolism and Toxicology 2:345-9.
72. Jacobs, A., 2008a. Use of minipigs for evaluation of FDA-regulated products. Lansdowne, Virginia. Presentation at the Inaugural Meeting of the North American Minipig Research Forum.
73. Jacobs, A., 2008b. Mini-pigs as an alternative non-rodent species in toxicology and safety studies. Lecture given as part of the Society of Toxicology Continuing Education Courses, March 16, 2008.
74. Jimenez, C., de Gracia, R., Aguilera, A. et al. 2008. In situ kidney insonation with microbubble contrast agents does not cause renal tissue damage in a porcine model. Journal of Ultrasound in Medicine 27:1607-15
75. Kalervo, H., Väänänen, J.S., and Lehenkari, P., 1996. Mechanism of osteoclast-mediated bone resorption. Journal of Bone and Mineral Metabolism 14(4):187-92.
76. Klein, A., Babilas, P., Karrer, S., Landthaler, M. et al., 2008. Photodynamic therapy in dermatology-An update 2008. Journal der Deutschen Dermatologischen Gesellschaft, 6:839-45.
77. Kore, A.M., 1990. Toxicology of nonsteroidal anti inflammatory drugs. Veterinary Clinics of North America: Small Animal Practice 20(2):419-30.
78. Kunecatechins, Anonymous, 2006a. FDA-CDER Clinical Pharmacology Biopharmaceutics Review for NDA 21-902. [021902s000_clinpharmr].
79. Kunecatechins, Anonymous, 2006b. FDA-CDER Pharmacology Review for NDA 21-902. Date of review submission to Division File System (DFS): 13JUN2006. [021902s000_pharmr].
80. Kunecatechins, Anonymous, 2008. FDA CDER Label for NDA 21-902. Dated 19SEP2008. [Label 021902/S-017 (19SEP2008)].
81. Lanreotide, Anonymous, 2007. FDA CDER Pharmacology review part 01 for NDA 22-074. Dated 21AUG2007. [022074s000_PharmR_P1 (21AUG2007)].
82. Lidocaine Hydrochloride, Anonymous 2007a. FDA CDER Label for NDA 22-114. Revised AUG2007. [Label 02211/S-000 (revised AUG2007)].
83. Lidocaine Hydrochloride, Anonymous 2007b. FDA CDER Pharmacology review for NDA 22-114. Dated 30JUL2007. [PharmR 022114/S-000 (30JUL2007)].
84. Madjar, H., Prompeler, H.J., Del Favero, C. et al., 2000. A new Doppler signal enhancing agent for flow assessment in breast lesions. European Journal of Ultrasound 12(2):123-30.
85. Mainigi, K.D., 2007. Minipig-A suitable model for assessing the safety and efficacy of topical drug products. Poster presented at IUTOX 2007-The XI International Congress of Toxicology, Montreal, Canada.
86. Maisch, T., Santarelli, F., Schreml, S. et al., 2010. Fluorescence induction of protoporphyrin IX by a new 5-aminolevulinic acid nanoemulsion used for photodynamic therapy in a full-thickness ex vivo skin model. Experimental Dermatology 19(8):e302-5.
87. Makin, A. et al., 2009. Minipig in Pharmacology, Pharmacokinetic and Toxicological Safety Evaluation Studies, Vol. 1. Newsletter from LAB Research, Laval, Quebec, Canada.
88. Meingassner, J.G., Kowalsky, E., Schwendinger, H. et al., 2003. Pimecrolimus does not affect Langerhans cells in murine epidermis. British Journal of Dermatology 149(4):853-7
89. Meloxicam, Anonymous, 1999a. FDA CDER Pharmacology Review Part 1. Dated September 17 1999. [020938_Meloxicam_pharmr_P1 (17SEP1999)].
90. Meloxicam, Anonymous, 1999b. FDA CDER Pharmacology Review Part 2. Dated September 17 1999. [020938_Meloxicam_pharmr_P2 (17SEP1999)].
91. Meloxicam, Anonymous, 2008. FDA CDER Label. Dated 30 September 2008. [Label 021530/S-006; 020938/S-018 (2008-jun-30)].
92. Mequinol Tretinoin, Anonymous, 1998. FDA CDER Medical/Clinical Review for NDA 20-922. [Medical/Clinical Review 020922s-000 Part 01 (1998-nov-23)].
93. Mequinol Tretinoin, Anonymous, 1999. FDA CDER Pharmacology Review for NDA 20-922. Pharmacology Review 020922/S-000 (1999-mar-30).
94. Methyl Aminolevulinate, Anonymous, 2002. FDA CDER Pharmacology Review for NDA 21-415. Dated 4 August 2002. [021415s-000 (2002-aug-04)].
95. Methyl Aminolevulinate, Anonymous, 2004. FDA CDER Label for NDA 21-415. [021415s-001 27JUL2004].
96. Minoxidil, Anonymous, 2005. FDA-CDER Pharmacology Review for NDA 21-812. Signed SEP/27/2005. [021812s000_PharmR].
97. Nakagawa, H., 2006. Comparison of the efficacy and safety of 0.1% tacrolimus ointment with topical corticosteroids in adult patients with atopic dermatitis: Review of randomised, double-blind clinical studies conducted in Japan. Clinical Drug Investigation 26(5):235-46.
98. Nghiem, P., Pearson, G., and Langley, R.G., 2002. Tacrolimus and pimecrolimus: From clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. Journal of the American Academy of Dermatology 46:228-41.
99. Oyen, R., 2005. Safety of ultrasound contrast agents. In H.S. Thomsen (Ed.), Contrast Media Safety Issues and ESUR Guidelines. Springer Verlag, Berlin, Heidelberg.
100. Peters, T., (2005). Pigs/Minipigs as the Second Species in Toxicology Studies-A Regulatory Perspective. Copenhagen: Presentation at the European Society of Toxicological Pathology.
101. Pimecrolimus, Anonymous, 2001a. FDA CDER Pharmacology Review for NDA 21-302. [021302/S-000 Part 04 (2001-sep-12)].
102. Pimecrolimus, Anonymous, 2001b. FDA CDER Pharmacology Review for NDA 21-302. [021302/S-000 Part 05 (2001-sep-12)].
103. Pimecrolimus, Anonymous, 2007. FDA CDER Label for NDA 21-302. [Label 021302s-012 (2007-aug-14)].
104. Pramipexole, Anonymous, 1997. FDA CDER Pharmacology Review for NDA 20-667 part 8. [020667a_pharmr_P8].
105. Pramipexole, Anonymous, 2005. EMA- EPAR Scientific Discussion.
106. Pramipexole, Anonymous, 2010. EMA-EPAR Product Information [updated version, July 2010].
107. Quinupristin Dalfopristin, Anonymous, 1998. FDA CDER Pharmacology Review for NDA. Dated 27JAN1998. [PharmR050748s-000 (27JAN1998)].
108. Retapamulin, Anonymous, 2007a. FDA CDER Medical Review for NDA 22-055. Document dated APR2007. [022055s000_MedR].
109. Retapamulin, Anonymous, 2007b. EMA Altargo EPAR-Scientific Discussion [19JUN2007].
110. Rickes, R., Uhle, C., Kahl, S. et al., 2006. Echo enhanced ultrasound: A new valid initial imaging approach for severe acute pancreatitis. Gut 2006, 55:74-8
111. Ring, J., Möhrenschlager, M., and Henkel, V., 2008. The US FDA ‘black box’ warning for topical calcineurin inhibitors: An ongoing controversy. Drug Safety 31(3):185-98.
112. Rivastigmine, Anonymous, 2007a. FDA CDER Label for NDA 22-083. Dated 09JUL2007. [022083/S-000 (09JUL2007)].
113. Rivastigmine, Anonymous, 2007b. FDA CDER Pharmacology review part 01 for NDA 22-083. Dated 06JUL2007. [022083/S-000 Part 01 (06JUL2007)].
114. Rotigotine, Anonymous, 2006a. FDA CDER Pharmacology Review 1 for NDA 21-829. Memorandum dated March 1, 2006. [021829s000_PharmR_P1].
115. Rotigotine, Anonymous, 2006b. FDA CDER Pharmacology Review 2 for NDA 21-829. Memorandum dated February 27 2006. [021829s000_PharmR_P2].
116. Ruffolo, R.R. and Feuerstein, G.Z., 1997. Pharmacology of carvedilol: Rationale for use in hypertension, coronary artery disease, and congestive heart failure. Cardiovascular Drugs and Therapy 11(suppl 1):247-56.
117. Ruffolo, R.R., Boyle, D.A., Venuti, R.P. et al. 1993. Preclinical and clinical pharmacology of carvedilol. Journal of Human Hypertension 7(Suppl 1):S2-15.
118. Selegiline, Anonymous, 2004. FDA CDER Pharmacology Review for NDA 21-336/21-708. Memorandum dated January 1, 2004 [021336s000_021708s000_PharmR_Part1].
119. Selegiline, Anonymous, 2006. FDA CDER Label for NDA 21-336/21-708. [021336s000_021708s000_printed label].
120. Spergel, J.M. and Leung, D.Y., 2006. Safety of topical calcineurin inhibitors in atopic dermatitis: Evaluation of the evidence. Current Allergy and Asthma Reports 6(4):270-4.
121. Sponer, G., Strein, K., Bartsch, W. et al., 1992. Vasodilatory action of carvedilol. Journal of Cardiovascular Pharmacology 19(Suppl 1):S5-11.
122. Stoppolino, G., Prisco, F., Santinelli, R. et al., 1983. Potential hazards of topical steroid therapy. American Journal of Diseases of Children 137:1130-1.
123. Sulphur Hexafluoride, Anonymous, 2000. FDA-CDER Pharmacology Review for NDA 21-135. Date of Review SEP/07/2000. [21135_Venofer_pharmr_P1].
124. Sulphur Hexafluoride, Anonymous, EMA. 2004. Sulphur Hexafluoride-Scientific Discussion. European Medicines Agency.
125. Sulphur Hexafluoride, Anonymous, EMA. 2007. Sulphur Hexafluoride-EPAR summary report for the public. European Medicines Agency.
126. Tacrolimus, Anonymous, 2000a. FDA CDER Pharmacology Review Part 2 for NDA 50-777. [050777/S-000 Part 02 (2000-aug-03)].
127. Tacrolimus, Anonymous, 2000b. FDA CDER Pharmacology Review Part 3 for NDA 50-777. [050777/S-000 Part 03 (2000-aug-03)].
128. Tacrolimus, Anonymous, 2005. FDA CDER Label for NDA Label 50-777. [050777s-012 (2005-nov-30)].
129. Tapentadol Hydrochloride, Anonymous, 2008. FDA CDER Pharmacology review part 02 for NDA 22-304. Dated 18NOV2008. [PharmR 022304/S-000 Part 02 (18NOV2008)].
130. Tazarotene, Anonymous, 1996. FDA CDER Pharmacology review part 01 for NDA 20-600. Date stamped 28APR1996. [20600_TAZORAC_0.05%25_AND_0.1%25_PHARMR_P1 (date stamped 28APR1996)].
131. Tazarotene, Anonymous, 2001a. FDA CDER Pharmacology review part 01 for NDA 21-184. Dated 19SEP2001. [PharmR 021184s-001 Part 01 (19SEP2001)].
132. Tazarotene, Anonymous, 2001b. FDA CDER Pharmacology Review Part 2 for NDA 21-184. [Pharmacology Review 021184/S-001 Part 01 (2001-jul-29)].
133. Tazarotene, Anonymous, 2002. FDA CDER Label for NDA 21-184. Dated 30SEP2002. [Label 021184/S-002 (30SEP2002)].
134. Tazarotene, Anonymous, 2002a. FDA CDER Label for NDA 21-184. [Label 021184/S-002 (2002-aug-31)].
135. Tazarotene, Anonymous, 2002b. FDA CDER Pharmacology Review Part 2 for NDA 21-184. [021184s-002 (2002-jan-18)].
136. Tazarotene, Anonymous, 2003. FDA CDER Label for NDA 20-600. [Label 020600s-003/S-005 (2003-nov-30)].
137. Tazarotene, Anonymous, 2003. FDA CDER Label for NDA 20-600. Dated 30NOV2003. [Label 020600s-003/S-005 (30NOV2003)].
138. Teitelbaum, S.L., 2000. Bone resorption by osteoclasts. Science 289(5484):1504-8.
139. Telavancin, Anonymous, 2009. FDA CDER Pharmacology Review for NDA 22-110, Dated 03SEP2009. [Pharmacology Review 022110s-000 (03SEP2009)].
140. Thaçi, D. and Salgo, R., 2010. Malignancy concerns of topical calcineurin inhibitors for atopic dermatitis: Facts and controversies. Clinics in Dermatology 28(1):52-6.
141. Türck, D., Roth, W., and Busch, U., 1996. A review of the clinical pharmacokinetics of meloxicam. British Journal of Rheumatology 35(Suppl 1):13-16.
142. van der Laan, J.W., Brightwell, J., McAnulty, P. et al., 2010. Regulatory acceptability of the minipig in the development of pharmaceuticals, chemicals and other products. Journal of Pharmacological and Toxicological Methods. 62(2): 184-95.
143. Van Vleet J.F., Herman E.H., and Ferrans, V.J., 1984. Cardiac morphologic alterations in acute minoxidil cardiotoxicity in miniature swine. Experimental and Molecular Pathology 41(1):10-25.
144. Wu, K.M., Ghantous, H., and Birnkrant, D.B., 2008. Current regulatory toxicology perspectives on the development of herbal medicines to prescription drug products in the United States. Food and Chemical Toxicology 46(8):2606-10.